Review the side-effects of Obinutuzumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.
If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.
Gastrointestinal: Diarrhea, constipation, indigestion, loss of appetite
Nervous system: Dizziness, confusion, difficulty in speech or to walk, loss of balance
Respiratory: Cough, nasal congestion, sneezing, inflammation of the sinuses, nasopharyngitis
Musculoskeletal: Joint pain, pain in the extremities, muscle pain or cramps
Blood: Low levels of neutrophils, lymphocytes, white blood cells
Lab abnormalities: Decreased levels of calcium, potassium, sodium, and phosphate in the blood, increased liver enzymes, and creatinine levels
Others: Headache, itching, fever, weakness, vision problems
Women of reproductive potential living with active male partners should follow an effective contraceptive measure during obinutuzumab treatment and must continue the contraception for at least 18 months after the last dose of obinutuzumab.
Inspect the obinutuzumab vials and the diluted solution for the presence of any visible solid matter or discoloration before administering it to the patient.
If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.
Gastrointestinal: Diarrhea, constipation, indigestion, loss of appetite
Nervous system: Dizziness, confusion, difficulty in speech or to walk, loss of balance
Respiratory: Cough, nasal congestion, sneezing, inflammation of the sinuses, nasopharyngitis
Musculoskeletal: Joint pain, pain in the extremities, muscle pain or cramps
Blood: Low levels of neutrophils, lymphocytes, white blood cells
Lab abnormalities: Decreased levels of calcium, potassium, sodium, and phosphate in the blood, increased liver enzymes, and creatinine levels
Others: Headache, itching, fever, weakness, vision problems
Other Precautions :
Breastfeeding mothers should be advised not to breastfeed their babies during and 18 months after the obinutuzumab treatment is stopped.Women of reproductive potential living with active male partners should follow an effective contraceptive measure during obinutuzumab treatment and must continue the contraception for at least 18 months after the last dose of obinutuzumab.
Inspect the obinutuzumab vials and the diluted solution for the presence of any visible solid matter or discoloration before administering it to the patient.
